Clinical Data

An arrow incrementally going up stairs before pointing straight up Blue background
Biotech

ESMO: Daiichi, Merck move ovarian cancer ADC toward pivotal test

The partners saw a 50.5% response rate in a study that informed the selection of their phase 3 dose.
Nick Paul Taylor Oct 20, 2025 10:45am
positive negative up down good bad mixed

Roche heads to FDA as eye disease trials yield mixed data

Oct 20, 2025 9:28am
reshuffle pipeline target reorganize shift change

ESMO: Exelixis' TKI reduces risk of death by 20%

Oct 20, 2025 2:30am
GSK ESMO

GSK says 'stay tuned' for more ADC data as Hansoh posts 49% ORR

Oct 19, 2025 10:40am
Roche ESMO

ESMO: Roche wants oral SERD to benefit 'all comers'

Oct 18, 2025 1:00am
weight loss from cancer

ESMO: Pfizer sees year-long weight gain in cancer patients

Oct 17, 2025 12:45pm